Stocks News

LAST PRICE
188.6000
TODAY'S CHANGE (%)
Trending Down-7.2700 (-3.7116%)

Bid / Lots
188.3700/ 1
Ask / Lots
188.8300/ 8
Open / Previous Close
195.7700 / 195.8700
Day Range
Low 188.0400
High 199.4100
52 Week Range
Low 95.0200
High 219.3400
Volume
91,196
below average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Today
- Krystal Biotech to Present at Stifel 2024 Healthcare Conference, from 7 hours ago by Dow Jones
  7 hours ago by Dow Jones
  Companies Mentioned: KRYS
  
  Krystal Biotech to Present at Stifel 2024 Healthcare Conference
  
  PITTSBURGH, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in the Stifel 2024 Healthcare Conference on November 18, 2024, in New York. Krish S. Krishnan, Chairman and Chief Executive Officer, will take part in a fireside chat scheduled at 10:55 am ET and host investor meetings throughout the day.
Nov 6, 2024
- Krystal Biotech to Present at Guggenheim Securities Healthcare Innovation Conference, from 7:00AM ET on Wednesday Nov 06, 2024 by Dow Jones
  7:00AM ET on Wednesday Nov 06, 2024 by Dow Jones
  Companies Mentioned: KRYS
  
  Krystal Biotech to Present at Guggenheim Securities Healthcare Innovation Conference
  
  PITTSBURGH, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in the Guggenheim Securities Healthcare Innovation Conference on November 12, 2024, in Boston. Krish S. Krishnan, Chairman and Chief Executive Officer, will take part in a fireside chat scheduled at 1:30 pm ET and host investor meetings throughout the day.
Nov 5, 2024
- DJ Krystal Biotech Is Maintained at Neutral by Citigroup, from 9:59AM ET on Tuesday Nov 05, 2024 by Dow Jones
  9:59AM ET on Tuesday Nov 05, 2024 by Dow Jones
  Companies Mentioned: KRYS
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/KRYS/analyst-ratings
  
  (END) Dow Jones Newswires
  
  November 05, 2024 09:59 ET (14:59 GMT)
- DJ Krystal Biotech Price Target Maintained With a $221.00/Share by HC Wainwright & Co., from 9:49AM ET on Tuesday Nov 05, 2024 by Dow Jones
  9:49AM ET on Tuesday Nov 05, 2024 by Dow Jones
  Companies Mentioned: KRYS
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/KRYS/analyst-ratings
  
  (END) Dow Jones Newswires
  
  November 05, 2024 09:49 ET (14:49 GMT)
Nov 4, 2024
- Krystal Biotech's Q3 Net Income Falls, Revenue Rises, from 8:34AM ET on Monday Nov 04, 2024 by MT Newswires
  8:34AM ET on Monday Nov 04, 2024 by MT Newswires
  Companies Mentioned: KRYS
  08:34 AM EST, 11/04/2024 (MT Newswires) -- Krystal Biotech (KRYS) reported Q3 net income Monday of $0.91 per diluted share, down from $2.79 a year earlier. Analysts polled by Capital IQ expected $0.90. Net revenue for the quarter ended Sept. 30 was ...

Today
- DJ Arcellx Is Maintained at Buy by Truist Securities, from 1 hour ago by Dow Jones
  1 hour ago by Dow Jones
  Companies Mentioned: ACLX
- Avidity Biosciences Announces New Precision Cardiology Development Candidates to Treat Rare Genetic Cardiomyopathies and Provides First Look at Next-Generation Technology Innovations, from 7 hours ago by PR Newswire
  7 hours ago by PR Newswire
  Companies Mentioned: RNA
- Avidity Biosciences Announces New Precision Cardiology Development Candidates to Treat Rare Genetic Cardiomyopathies and Provides First Look at Next-Generation Technology Innovations, from 7 hours ago by Dow Jones
  7 hours ago by Dow Jones
  Companies Mentioned: RNA
- --Truist Boosts Price Target on Arcellx to $136 From $87, Keeps Buy Rating, from 7 hours ago by MT Newswires
  7 hours ago by MT Newswires
  Companies Mentioned: ACLX
Yesterday
- Crinetics Pharmaceuticals Announces November 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4), from 21 hours ago by Dow Jones
  21 hours ago by Dow Jones
  Companies Mentioned: CRNX
Nov 8, 2024
- DJ Arcellx Is Maintained at Buy by HC Wainwright & Co., from 2:51PM ET on Friday Nov 08, 2024 by Dow Jones
  2:51PM ET on Friday Nov 08, 2024 by Dow Jones
  Companies Mentioned: ACLX
- DJ Arcellx Is Maintained at Overweight by Piper Sandler, from 8:32AM ET on Friday Nov 08, 2024 by Dow Jones
  8:32AM ET on Friday Nov 08, 2024 by Dow Jones
  Companies Mentioned: ACLX
- DJ Arcellx Is Maintained at Buy by Needham, from 7:33AM ET on Friday Nov 08, 2024 by Dow Jones
  7:33AM ET on Friday Nov 08, 2024 by Dow Jones
  Companies Mentioned: ACLX
Nov 7, 2024
- Avidity Biosciences Reports Third Quarter 2024 Financial Results and Recent Highlights, from 4:05PM ET on Thursday Nov 07, 2024 by PR Newswire
  4:05PM ET on Thursday Nov 07, 2024 by PR Newswire
  Companies Mentioned: RNA
- Avidity Biosciences Reports Third Quarter 2024 Financial Results and Recent Highlights, from 4:05PM ET on Thursday Nov 07, 2024 by Dow Jones
  4:05PM ET on Thursday Nov 07, 2024 by Dow Jones
  Companies Mentioned: RNA

Krystal Biotech Inc
NASDAQ:KRYSUnited States

Search Criteria

Today

Krystal Biotech to Present at Stifel 2024 Healthcare Conference, from 7 hours ago by Dow Jones

Nov 6, 2024

Krystal Biotech to Present at Guggenheim Securities Healthcare Innovation Conference, from 7:00AM ET on Wednesday Nov 06, 2024 by Dow Jones

Nov 5, 2024

DJ Krystal Biotech Is Maintained at Neutral by Citigroup, from 9:59AM ET on Tuesday Nov 05, 2024 by Dow Jones

DJ Krystal Biotech Price Target Maintained With a $221.00/Share by HC Wainwright & Co., from 9:49AM ET on Tuesday Nov 05, 2024 by Dow Jones

Nov 4, 2024

Krystal Biotech's Q3 Net Income Falls, Revenue Rises, from 8:34AM ET on Monday Nov 04, 2024 by MT Newswires

Peers Headlines

Today

DJ Arcellx Is Maintained at Buy by Truist Securities, from 1 hour ago by Dow Jones

Avidity Biosciences Announces New Precision Cardiology Development Candidates to Treat Rare Genetic Cardiomyopathies and Provides First Look at Next-Generation Technology Innovations, from 7 hours ago by PR Newswire

Avidity Biosciences Announces New Precision Cardiology Development Candidates to Treat Rare Genetic Cardiomyopathies and Provides First Look at Next-Generation Technology Innovations, from 7 hours ago by Dow Jones

--Truist Boosts Price Target on Arcellx to $136 From $87, Keeps Buy Rating, from 7 hours ago by MT Newswires

Yesterday

Crinetics Pharmaceuticals Announces November 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4), from 21 hours ago by Dow Jones

Nov 8, 2024

DJ Arcellx Is Maintained at Buy by HC Wainwright & Co., from 2:51PM ET on Friday Nov 08, 2024 by Dow Jones

DJ Arcellx Is Maintained at Overweight by Piper Sandler, from 8:32AM ET on Friday Nov 08, 2024 by Dow Jones

DJ Arcellx Is Maintained at Buy by Needham, from 7:33AM ET on Friday Nov 08, 2024 by Dow Jones

Nov 7, 2024

Avidity Biosciences Reports Third Quarter 2024 Financial Results and Recent Highlights, from 4:05PM ET on Thursday Nov 07, 2024 by PR Newswire

Avidity Biosciences Reports Third Quarter 2024 Financial Results and Recent Highlights, from 4:05PM ET on Thursday Nov 07, 2024 by Dow Jones